The development of hepatic veno-occlusive disease following bone marrow transplantation is associated with high-dose combination cytoreductive therapy. Experimental models have suggested that drug-induced injury to hepatic sinusoidal endothelial cells is involved in the pathogenesis of this syndrome. Hyaluronic acid is a polysaccharide that is metabolized, almost exclusively, by hepatic sinusoidal endothelial cells. The aim of the present study was to evaluate serum hyaluronic acid as a marker for endothelial cell injury in patients with veno-occlusive disease following bone marrow transplantation. Hyaluronic acid was measured in sera from patients with and without veno-occlusive disease using an enzyme-linked protein binding assay. Mean peak serum hyaluronic acid levels were significantly greater in patients who had a diagnosis of VOD compared to those transplant patients who did not, 1173.4 ± 982.9 vs 444.9 ± 735.6 ng/ml (P = 0.01). Serial serum samples obtained from a separate cohort of patients also demonstrated that serum hyaluronic acid levels were higher in patients with moderate or severe veno-occlusive disease compared to those with none or mild disease at days 7, 17 and 25 following transplantation (greatest difference at day 25: 366 ± 327 vs 126 ± 151, P = 0.01). Serum hyaluronic acid levels are increased in veno-occlusive disease and increase over time in patients with severe disease. Further studies are required to determine if elevated serum hyaluronic acid levels are due to decreased clearance by injured hepatic sinusoidal endothelial cells or increased production from early hepatic fibrogenesis associated with the acute liver injury. Bone Marrow Transplantation ( Hepatic veno-occlusive disease (VOD) is a life-threatening complication of bone marrow transplantation (BMT) that is defined by the appearance of jaundice, tender hepatomegaly, and ascites.
Hepatic veno-occlusive disease (VOD) is a life-threatening complication of bone marrow transplantation (BMT) that is defined by the appearance of jaundice, tender hepatomegaly, and ascites. [1] [2] [3] Clinical manifestations of VOD usually occur within 3 weeks of transplant and vary in their severity. Mild VOD may be self-limited and resolve with supportive care, while severe VOD causes progressive hepatic synthetic dysfunction and complications of portal hypertension that culminate in multi-organ failure and death. 2 The histologic changes of VOD occur predominantly in the centrizonal region of the hepatic lobule and are characterized by subendothelial edema, occlusion of terminal hepatic venules, hepatocyte necrosis, and sinusoidal fibrosis. 4 The incidence of VOD following transplantation ranges between 10% and 54% depending on the cytoreductive regimen and the criteria used to define the syndrome. 2, 3, 5 The development of VOD has been strongly associated with high-dose combination cytoreductive therapy, particularly regimens that contain cyclophosphamide coupled with total body irradiation, busulfan, carmustine, or etoposide. 2, 3 Several studies have provided evidence that injury to hepatic sinusoidal endothelial cells by chemotherapeutic agents is an early event in the pathogensis of VOD. 6, 7 In cell culture, isolated sinusoidal endothelial cells were more susceptible to injury than were hepatocytes when incubated with dacarbazine, an agent associated with VOD. 6 Similarly, metabolites of cyclophosphamide appeared to be selectively toxic to sinusoidal endothelial cells when they were cocultured with hepatocytes. 7 Hyaluronic acid (HA) is a polysaccharide of high molecular weight that is found in the extracellular matrix. 8, 9 HA is synthesized throughout the body in mesenchymal cells and translocated into the extracellular spaces. 8, 9 Prostaglandin E2, fibroblast growth factor, and transforming growth factor-␤ have been shown to stimulate the synthesis of HA. 10 Hyaluronic acid is cleared, almost exclusively, by hepatic sinusoidal endothelial cells (SEC). [9] [10] [11] HA uptake into SEC is accomplished via receptor-mediated endocytosis followed by degradation by lysosomal hyaluronidase. 10 Serum hyaluronic acid is elevated in patients with chronic liver disease. [10] [11] [12] Serum levels of HA correlated directly with the severity of histologic injury in patients with primary biliary cirrhosis and, recently, elevation of serum HA concentrations have been shown to be predictive of the presence of cirrhosis in patients with chronic hepatitis C. 11, 12 In liver transplant patients with acute cellular rejection HA levels were also increased. 13 The mechanism of increased serum HA in patients with liver disease is not clear but may reflect decreased clearance by damaged hepatic sinusoidal endothelial cells, as may be seen with cellular rejection or shunting of portal blood flow as may be seen in cirrhosis. Alternatively, increased production of HA during the course of hepatic fibrogenesis may also lead to increased levels. 10, 11, 13 The aim of the present study was to evaluate serum hyaluronic acid as a marker of sinusoidal endothelial cell injury in patients with VOD following bone marrow transplantation and to correlate serial measurements of HA with the evolution of VOD and disease severity.
Materials and methods
Veno-occlusive disease was diagnosed in patients who developed hyperbilirubinemia and evidence of fluid retention within 4 weeks of bone marrow transplantation in accordance with previously published criteria. 2, 14 History, physical examination, imaging studies, and appropriate serologic tests excluded other causes of hepatic dysfunction. Transjugular liver biopsies were available in some patients and were evaluated for changes of centrizonal hemorrhagic necrosis, occlusion of terminal hepatic venules, and sinusoidal fibrosis to further support the diagnosis of VOD. 4, 14, 15 The study was conducted in two phases. In the initial pilot study, sera for HA measurement were collected from patients who were diagnosed with progressive VOD and stored frozen at −70°C until assayed. Controls consisted of three groups: patients who underwent BMT not complicated by VOD, patients with mild chronic hepatitis C without histologic evidence of hepatic fibrosis, and patients with cirrhosis as shown on liver biopsy or with evidence of hepatic synthetic decompensation. Hyaluronic acid was measured using an enzyme-linked protein binding assay kit that uses HA binding protein as the capture molecule (Chugai Pharmaceutical, Tokyo, Japan; REAADS Medical Products, Denver, CO, USA). In patients for whom several serum samples were available, the serum sample with the highest HA value was used for data analysis. Mean peak serum HA levels were compared between patients with VOD and controls.
In the second phase of the study, sera were collected prospectively at days −1 (during cytoreductive therapy), +7, +17, +25 and +30 (within the first month following bone marrow transplantation). By convention, day zero is day of bone marrow infusion. A subset of 28 patients (10 without and 18 with varying degrees of VOD) was selected retrospectively for serial HA determinations. The severity of VOD was graded as mild, moderate and severe according to previously published criteria. 2 Briefly, patients with mild VOD had no apparent adverse effects from liver disease and the signs, symptoms, and laboratory abnormalities were completely reversible. Patients with liver disease requiring specific diuretic therapy, pain medication, or treatment of associated renal or cardiopulmonary dysfunction but who eventually had normalization of liver abnormalities were classified as moderate VOD, while patients whose signs, symptoms, and laboratory abnormalities did not resolve by day 100 post-BMT or who died were classified as severe VOD. Mean serum HA concentrations at each time-point were compared between patients with and without VOD and after stratification for disease severity using the MannWhitney U test.
Sera were collected from patients who gave written informed consent under protocols approved by the Human Investigations Committees of the two institutions participating in this study.
Results
In the pilot phase of the study, 40 patients undergoing bone marrow transplantation at Emory University Hospital were studied; eight with severe VOD and 32 who did not develop VOD. The indications for BMT included non-Hodgkin's lymphoma (14 patients), breast cancer (12 patients), multiple myeloma (five patients), acute or chronic myeloid leukemia (five patients), and Hodgkin's lymphoma, chronic lymphocytic leukemia, aplastic anemia and hypereosinophilic syndrome (one patient each). Several conditioning regimens were used: cyclophosphamide combined with either busulfan and VP-16, thiotepa and carboplatinum, Ara-C and busulfan, or total body irradiation. The mean age was 44 ± 9.5 years. Twenty-one patients were female.
In patients with VOD, mean serum bilirubin was 9.7 ± 4.2 mg/dl, compared to 1.2 ± 1.8 (P Ͻ 0.001) in BMT patients without VOD. Mean prothrombin time was 21.2 ± 13.8 vs 13.5 ± 1.0 seconds (P Ͻ 0.001) and serum creatinine was 3.3 ± 2.0 compared to 0.9 ± 0.6 in the VOD and non-VOD patients, respectively (P Ͻ 0.001).
Mean peak serum HA levels were significantly greater in BMT patients who had a diagnosis of VOD than in those transplant patients who did not, 1173.4 ± 982.9 vs 444.9 ± 735.6 ng/ml (P = 0.01, Figure 1 ). Both groups had higher levels of serum HA than did the control group of patients with mild chronic hepatitis C (45.3 ± 39.1, P Ͻ 0.01). In contrast, patients without VOD following BMT had levels of HA similar to patients with cirrhosis (370.4 ± 354.1, P = NS), although both were significantly lower than in patients with VOD ( Figure 1 ). Four patients without VOD had levels of HA exceeding 1000 ng/ml. One of these patients was jaundiced (total bilirubin = 9.3 mg/dl) with clinical features of VOD, although transjugular liver biopsy did not demonstrate changes consistent with VOD.
With 400 ng/ml as a cutoff, the sensitivity of an increased serum HA for the diagnosis of severe VOD in patients undergoing BMT was 88% with a specificity of 78%. Paired sera obtained at the beginning of cytoreductive therapy (mean = 1 day after initiation of chemotherapy and 6.5 days prior to BMT) and following BMT (mean = 7 days after stem cell infusion) were available from 16 patients who did not develop VOD. Serum HA levels increased following BMT in this group (pre-BMT = 39.5 ± 52.3 vs post-BMT = 354.9 ± 465 ng/ml, P Ͻ 0.01). During this pilot study, serial serum samples were available from one patient who developed severe VOD during observation. Elevations of serum HA preceded the rise in serum bilirubin by 1 week (Figure 2 ).
In the serial sampling phase of the study, 28 patients transplanted at Fred Hutchinson Cancer Research Center were studied. The indications for transplantation were chronic myeloid leukemia in 10 patients, acute myeloid leukemia in 10, acute lymphocytic leukemia or myelodysplastic syndrome in three patients each, and non-Hodgkin's lymphoma in two patients. Conditioning was with cyclophosphamide combined with busulfan, total body irradiation, or total bone marrow irradiation. The average age was 36.4 ± 11.7 years and 20 patients were female. Mean serum bilirubin levels progressively rose in patients with moderate or severe VOD compared to patients with no or mild VOD and were significantly higher from day 7 (4.2 ± 3.1 vs 1.3 ± 0.7 mg/dl, P Ͻ 0.004) and throughout follow-up (day 25: 7.2 ± 4.3 vs 1.6 ± 0.8 mg/dl, P = 0.0005).
Mean serum HA levels also rose in patients who Bone Marrow Transplantation developed VOD. Peak HA levels occurred at day 25 and were greater than in patients who did not develop VOD, although this was not statistically significant (242 ± 278 vs 146 ± 181, P = 0.3). When patients were stratified according to severity of VOD, those with moderate or severe VOD (n = 10) had significantly higher levels of HA than those with none or mild VOD (n = 18) at days 7, 17 and 25 post-BMT (day 25: 366 ± 327 vs 126 ± 151, P = 0.01) (Figure 3 ). Two patients with severe VOD expired prior to day 30 following BMT. The sensitivity and specificity for an HA level greater than 400 ng/ml for the diagnosis of moderate or severe VOD in this cohort were 50% and 77%, respectively.
Discussion
Several lines of experimental evidence suggest that the pathogenesis of veno-occlusive disease following bone marrow transplantation involves early injury to hepatic sinusoidal endothelial cells. 3, 6, 7 In the present study, we utilized serum levels of hyaluronic acid as a marker for hepatic sinusoidal endothelial cell injury in patients with VOD following bone marrow transplantation. We have shown that serum HA levels are significantly increased in patients who develop VOD compared to those without VOD.
The increase of serum HA levels in patients with VOD may be due to either decreased clearance of HA by injured sinusoidal endothelial cells (early changes) or from increased production of HA during fibrogenesis that may be seen with progressive VOD (late changes). The current data indicate that both of these factors may be responsible for the rise in serum HA. In BMT patients who never developed clinical VOD, paired sera showed a significant increase in HA levels following BMT, suggesting early subclinical hepatic SEC alterations. This finding is consistent with a study that blindly reviewed consecutive autopsy liver specimens from patients who had undergone BMT and found that clinical signs of VOD were absent from 13% of patients whose livers had histologic evidence of VOD. Furthermore, an increase in serum HA levels preceded the rise of serum bilirubin and clinical VOD in one patient in the pilot phase of this study from whom frequent serial samples were available. Unfortunately, this interesting observation could not be evaluated with more patients during the prospective phase of the study since the serial samples were collected at much greater time intervals. In a study that evaluated various plasma markers for endothelial cell injury and activation following BMT, increases of von Willebrand factor, tumor necrosis factor alpha, and ICAM-1 were also seen in patients after BMT, suggesting that SEC alterations occurred even in the absence of symptomatic VOD. 17 In addition, serum levels of plasminogen activator inhibitor-1, synthesized and released by endothelial cells, have been shown to be increased in patients with VOD following bone marrow transplantation. 18 The increases of serum HA may also be related to developing fibrosis during the course of VOD. In the pilot phase of the study, serum samples obtained an average of 17 days post-BMT from patients with severe VOD had elevated serum HA levels. Similarly in the prospective study, levels of HA were also significantly higher by day 17 and continued to increase to day 25 in patients with moderate and severe VOD compared to patients with no or mild disease. Hepatic sinusoidal fibrosis is a histologic feature of VOD that appears to correlate with severity of disease as measured by peak serum bilirubin values and the presence of ascites. 4 A preliminary report has also shown that serum markers of fibrogenesis, such as procollagen III peptide and tenascin, are increased during progressive VOD. 19 Thus, elevation of HA in the late stages of VOD, as shown in the present study, may represent an increase in HA production associated with fibrogenesis. Since these changes were more marked in patients with moderate and severe VOD, serum HA levels also appear to correlate with disease severity.
Using data from the pilot study with 400 ng/ml as a cutoff, the sensitivity and specificity of serum HA for the diagnosis of VOD is 88% and 78%, respectively. These results must be interpreted with caution since patients were selected for the development of severe VOD and compared to patients who did not have VOD. In the serial sampling phase of the study, the absolute values of serum HA and the sensitivity were lower than those seen in the pilot phase. This probably reflects the predominantly mild VOD that comprised this population. For the few patients with severe VOD, peak levels of HA and sensitivity were comparable to those seen in the pilot phase of the study. Defining the true clinical utility of this assay for the differential diagnosis of liver disease following bone marrow transplantation requires inclusion of patients with the entire spectrum of BMT-related jaundice, such as graft-versus-host disease, opportunistic infections, cholestasis associated with sepsis, and cholestasis related to cyclosporine therapy.
In summary, serum hyaluronic acid levels are increased in patients with VOD following bone marrow transplantation. Timing of the elevations of serum HA suggests two possible mechanisms: decreased HA clearance associated with early SEC injury from chemotherapeutic agents and increased production of HA associated with fibrogenesis in the later stages of progressive VOD. Further studies are required to evaluate the clinical and prognostic utility of serum hyaluronic acid measurements.
